Each year, TIAP’s members are granted more than $1.47 billion to fund their research and discovery activities. Such discoveries form the source of a vibrant scientific project pipeline, which – when guided through LAB150 and paired with the cutting-edge infrastructure and drug discovery expertise of Evotec – will result in an accelerated discovery timeline. The result? A validated source of new venture creation in Ontario, based on high-quality, business-driven opportunities to develop much needed therapies for global patient benefit.
